*Comments Due Date:* Comments regarding this information collection are best assured of having their full effect if received within 30 days of the date of this publication.

Dated: October 21, 2010.

Vivian Horovitch-Kelley,

NCI Project Clearance Liaison, National Institutes of Health.

[FR Doc. 2010–27330 Filed 10–28–10; 8:45 am] BILLING CODE 4140–01–P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

## Food and Drug Administration

[Docket No. FDA-2010-D-0378]

## Draft Compliance Policy Guide Sec. 690.800 Salmonella in Animal Feed; Availability; Extension of Comment Period

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice; extension of comment period.

**SUMMARY:** The Food and Drug Administration (FDA) is extending to December 31, 2010, the comment period for a notice of availability of a draft compliance policy guide (CPG) that appeared in the Federal Register of August 2, 2010 (75 FR 45130). In the document, FDA requested comments on its proposal that certain criteria should be considered in recommending enforcement action against animal feed or feed ingredients that are adulterated due to the presence of *Salmonella*. The Agency is taking this action in response to requests for an extension to allow interested persons additional time to submit comments.

**DATES:** Submit either electronic or written comments by December 31, 2010.

ADDRESSES: Submit electronic comments on the draft CPG to *http:// www.regulations.gov.* Submit written comments on the draft CPG to the Division of Dockets Management (HFA– 305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852.

FOR FURTHER INFORMATION CONTACT: Kim Young, Center for Veterinary Medicine (HFV–230), Food and Drug Administration, 7519 Standish Pl., MPN–4, rm. 106, Rockville, MD 20855, 240–276–9200, e-mail: *Kim.young@fda.hhs.gov.* 

#### SUPPLEMENTARY INFORMATION:

### I. Background

In the Federal Register of August 2, 2010 (75 FR 45130), FDA published a notice of availability of a draft CPG with a 90-day comment period to request comments on its proposal that certain criteria should be considered in recommending enforcement action against animal feed or feed ingredients that are adulterated due to the presence of Salmonella. The Agency has received a request for a 60-day extension of the comment period for the draft CPG. The request conveyed concern that the current 90-day comment period does not allow sufficient time to develop a meaningful or thoughtful response to the draft CPG. FDA has considered the request and is extending the comment period for the draft CPG for 60 days, until December 31, 2010.

#### **II. Request for Comments**

Interested persons may submit to the Division of Dockets Management (see **ADDRESSES**) either electronic or written comments on this document. It is only necessary to send one set of comments. It is no longer necessary to send two copies of mailed comments. Identify comments with the docket number found in brackets in the heading of this document. Received comments may be seen in the Division of Dockets Management between 9 a.m. and 4 p.m., Monday through Friday.

Dated: October 26, 2010.

### Dara Corrigan,

Associate Commissioner for Regulatory Affairs.

[FR Doc. 2010–27448 Filed 10–28–10; 8:45 am] BILLING CODE 4160–01–P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

# Centers for Disease Control and Prevention

## Advisory Board on Radiation and Worker Health (ABRWH or Advisory Board), National Institute for Occupational Safety and Health (NIOSH)

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), and pursuant to the requirements of 42 CFR 83.15(a), the Centers for Disease Control and Prevention (CDC), announces the following meeting of the aforementioned committee:

# Board Public Meeting Times and Dates (All Times Are Mountain Time)

8:15 a.m.–5:15 p.m., November 16, 2010.

8:15 a.m.–5:15 p.m., November 17, 2010.

8:15 a.m.–12 p.m., November 18, 2010

## Public Comment Times and Dates (All Times Are Mountain Time)

5:30 p.m.–7 p.m.,\* November 16, 2010.

5:30 p.m.–6:30 p.m.,\* November 17, 2010.

\*Please note that the public comment periods may end before the times indicated, following the last call for comments. Members of the public who wish to provide public comments should plan to attend public comment sessions at the start times listed.

*Place:* Hilton Santa Fe Historic Plaza, 100 Sandoval Street, Santa Fe, New Mexico; Phone: 505–988–2811; Fax: 505–986–6439. Audio Conference Call via FTS Conferencing. The USA toll-free dial-in number is 1–866–659–0537 with a pass code of 9933701.

*Status:* Open to the public, limited only by the space available. The meeting space accommodates approximately 150 people.

Background: The Advisory Board was established under the Energy Employees Occupational Illness Compensation Program (EEOICP) Act of 2000 to advise the President on a variety of policy and technical functions required to implement and effectively manage the new compensation program. Kev functions of the Advisory Board include providing advice on the development of probability of causation guidelines which have been promulgated by the Department of Health and Human Services (HHS) as a final rule, advice on methods of dose reconstruction which have also been promulgated by HHS as a final rule, advice on the scientific validity and quality of dose estimation and reconstruction efforts being performed for purposes of the compensation program, and advice on petitions to add classes of workers to the Special Exposure Cohort (SEC).

In December 2000, the President delegated responsibility for funding, staffing, and operating the Advisory Board to HHS, which subsequently delegated this authority to the CDC. NIOSH implements this responsibility for CDC. The charter was issued on August 3, 2001, renewed at appropriate intervals, and will expire on August 3, 2011.

*Purpose:* This Advisory Board is charged with (a) Providing advice to the Secretary, HHS, on the development of guidelines under Executive Order 13179; (b) providing advice to the Secretary, HHS, on the scientific validity and quality of dose